May 9th 2024
In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Study Suggests Panurothelial Carcinoma Warrants More Aggressive Surgical Treatment
January 26th 2016A study published in Scientific Reports by researchers from China indicates panurothelial carcinoma (panUCC) has a high risk of recurring, progressing, and disseminating after conservative surgery, leading to poor outcomes.
Read More
Bladder Cancer Diagnosis, Treatment, and Prevention May Be Aided by Tumor Suppressor Gene
January 22nd 2016Bladder cancer remains the costliest cancer to treat per capita, taking into account diagnostic testing, management, and long-term follow-up. Continued development of urine-based biomarker diagnostic tests may help replace the costly and more invasive techniques of imaging, cytology, and cystoscopy for cancer detection. Genome-wide expression and sequencing studies have identified genes and pathways considered key drivers of bladder cancer.
Read More
Dr. Elizabeth Plimack on Ipilimumab and PD-L1 Inhibitors in the Treatment of Bladder Cancer
January 14th 2016Plimack says the efficacy of PD-L1 inhibitors have been proven in the treatment of bladder cancer and are currently employed in the armamentarium of medical professionals. She adds as other cancer types further test both ipilimumab and PD-L1 inhibitors, oncologists will gain a better understanding of how both will continue to play a role in bladder cancer.
Watch
Dr. Jean Hoffman-Censits on the Results of a Phase II Trial Studying Atezolizumab in Bladder Cancer
January 13th 2016Hoffman-Censits says outside of the first-line therapy of cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression.
Watch
Padmanee Sharma discusses the constantly shifting landscape of immune response and how it differs from patient to patient. Sharma says in order to best treat a patient with bladder cancer, oncologists have to consider that immune response in patients will never be the same day to day.
Watch
Dr. James L. Gulley on Atezolizumab, Pembrolizumab, and Avelumab's Potential Uses in Bladder Cancer
January 11th 2016Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer, despite some widely-used agents, such as nivolumab and pembrolizumab, already being approved for other cancer types like melanoma and lung cancer, though not bladder cancer.
Watch
Further Research Into Checkpoint Blockade for Upper Tract Urothelial Cancers Needed
December 22nd 2015While results from ongoing trials with atezolizumab, pembrolizumab, nivolumab, and avelumab in bladder cancer are eagerly awaited, there is one subset of patients who require special attention - patients with upper tract urothelial cancer (UTUC).
Read More
Dr. Luciano Rossetti on the Function of Anti-PD-L1 Treatments in Bladder Cancer
November 18th 2015Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.
Watch
Bladder Cancer Biomarker May Lend New Diagnostic and Therapeutic Strategies
October 23rd 2015A new paper spotlights a potential biomarker and therapeutic target for bladder cancer. The authors say that although BC is recognized as a common and deadly malignancy, a lack of understanding of the molecular pathways involved has hindered development of effective treatments compared with progress made with other malignancies.
Read More
Dr. Andrea Apolo On Avelumab and its Effect on Locally Advanced or Metastatic Urothelial Carcinoma
October 14th 2015Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.
Watch
Biologic Immunotherapy for Bladder Cancer Receives FDA Advisory Hearing
October 5th 2015Telesta Therapeutics has been granted an FDA advisory hearing to discuss the biologics license application of its MCNA immunotherapy as treatment for high-risk nonmuscle invasive bladder cancer following first-line bacillus Calmette-Guerin (BCG).
Read More
Intravesical Immunotherapy Priority Review for Bladder Cancer Granted by FDA
August 31st 2015A priority review designation was recently assigned by the FDA to the intravesical immunotherapy MCNA as a treatment for patients who have high-risk non-muscle invasive bladder cancer, following first-line bacillus Calmette-Guérin (BCG) therapy.
Read More
Dr. Petrylak Discusses BCG for the Treatment of Patients With Non-Invasive Bladder Cancer
August 28th 2015Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.
Watch